- Home
- GALT vs ANIX Comparison
GALT vs ANIX Comparison
Compare GALT & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- ANIX
- Stock Information
- Founded
- GALT 2000
- ANIX 1982
- Country
- GALT United States
- ANIX United States
- Employees
- GALT N/A
- ANIX N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- ANIX Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- ANIX Health Care
- Exchange
- GALT Nasdaq
- ANIX Nasdaq
- Market Cap
- GALT 83.5M
- ANIX 88.9M
- IPO Year
- GALT N/A
- ANIX 1987
- Fundamental
- Price
- GALT $2.60
- ANIX $3.38
- Analyst Decision
- GALT Buy
- ANIX Strong Buy
- Analyst Count
- GALT 2
- ANIX 3
- Target Price
- GALT $6.00
- ANIX $9.00
- AVG Volume (30 Days)
- GALT 1.2M
- ANIX 236.6K
- Earning Date
- GALT 08-12-2025
- ANIX 05-28-2025
- Dividend Yield
- GALT N/A
- ANIX N/A
- EPS Growth
- GALT N/A
- ANIX N/A
- EPS
- GALT N/A
- ANIX N/A
- Revenue
- GALT N/A
- ANIX N/A
- Revenue This Year
- GALT N/A
- ANIX N/A
- Revenue Next Year
- GALT N/A
- ANIX N/A
- P/E Ratio
- GALT N/A
- ANIX N/A
- Revenue Growth
- GALT N/A
- ANIX N/A
- 52 Week Low
- GALT $0.73
- ANIX $2.07
- 52 Week High
- GALT $3.90
- ANIX $4.20
- Technical
- Relative Strength Index (RSI)
- GALT 70.66
- ANIX 57.87
- Support Level
- GALT $1.28
- ANIX $3.30
- Resistance Level
- GALT $1.36
- ANIX $3.80
- Average True Range (ATR)
- GALT 0.33
- ANIX 0.25
- MACD
- GALT 0.18
- ANIX 0.05
- Stochastic Oscillator
- GALT 52.40
- ANIX 61.47
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.